158 related articles for article (PubMed ID: 36270111)
41. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
42. New brefeldin A-cinnamic acid ester derivatives as potential antitumor agents: Design, synthesis and biological evaluation.
Jiang YY; Wu S; Wu YW; Gao Y; Chong D; Sun C; Wei MY; Gu YC; Shao CL; Gu Y
Eur J Med Chem; 2022 Oct; 240():114598. PubMed ID: 35849940
[TBL] [Abstract][Full Text] [Related]
43. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
44. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
45. Thiazolidinone-linked1,2,3-triazoles with monoterpenic skeleton as new potential anticancer agents: Design, synthesis and molecular docking studies.
Oubella A; El Mansouri AE; Fawzi M; Bimoussa A; Laamari Y; Auhmani A; Morjani H; Robert A; Riahi A; Youssef Ait Itto M
Bioorg Chem; 2021 Oct; 115():105184. PubMed ID: 34333421
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
47. 1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
Mareddy J; Suresh N; Kumar CG; Kapavarapu R; Jayasree A; Pal S
Bioorg Med Chem Lett; 2017 Feb; 27(3):518-523. PubMed ID: 28011214
[TBL] [Abstract][Full Text] [Related]
48. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and Molecular Docking of Some Novel 3-Thiazolyl-Coumarins as Inhibitors of VEGFR-2 Kinase.
Abolibda TZ; Fathalla M; Farag B; Zaki MEA; Gomha SM
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677750
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
51. New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study.
El Azab IH; El-Sheshtawy HS; Bakr RB; Elkanzi NAA
Molecules; 2021 Jan; 26(3):. PubMed ID: 33573040
[TBL] [Abstract][Full Text] [Related]
52. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
53. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.
Saleh NM; Abdel-Rahman AA; Omar AM; Khalifa MM; El-Adl K
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100085. PubMed ID: 33948983
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and biological evaluation of artemyrianolide H derivatives as potential antihepatoma agents.
Li TZ; Yang XT; Ma WJ; Ma YB; Li FJ; Wang YC; Chen JJ
Bioorg Chem; 2023 Aug; 137():106617. PubMed ID: 37267793
[TBL] [Abstract][Full Text] [Related]
55. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations.
Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH
Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621
[TBL] [Abstract][Full Text] [Related]
56. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
57. Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity.
Nunes PSG; da Silva G; Nascimento S; Mantoani SP; de Andrade P; Bernardes ES; Kawano DF; Leopoldino AM; Carvalho I
Bioorg Chem; 2021 Aug; 113():104982. PubMed ID: 34020277
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
59. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
[TBL] [Abstract][Full Text] [Related]
60. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
